CenTrial Logo

Is Rocatinlimab Safe and Effective for Treating Moderate-to-Severe Atopic Dermatitis?


Clinical trial reveals safe effective treatment for atopic dermatitis

Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by red, itchy, and scaly patches of skin. It can range from mild to severe, significantly impacting a person's quality of life, causing intense itching, sleep disturbances, and limiting daily activities. Severe atopic dermatitis can be associated with a higher risk of skin infections and require more intensive and prolonged treatment.

The severity of atopic dermatitis is often assessed by clinical scores such as the Eczema Area and Severity Index (EASI), which considers the extent and severity of the skin lesions, and the Investigator's Global Assessment, which rates the overall severity of the disease.

Clinical Trial

In a clinical trial, researchers investigated the use of rocatinlimab in treating moderate-to-severe atopic dermatitis. The drug targets a protein called OX40, which plays a role in the immune response and the development of T cells. By inhibiting this pathway, the drug is thought to reduce the inflammation associated with atopic dermatitis.

The study was a randomized, double-blind, placebo-controlled trial that included 274 adult patients with confirmed atopic dermatitis. Patients were randomized to receive subcutaneous injections of rocatinlimab or placebo every 2 or 4 weeks for up to 18 weeks, followed by an 18-week extension period and a 20-week follow-up. The primary endpoint was the percentage change from baseline in the Eczema Area and Severity Index score at week 16.

The results showed that all doses of rocatinlimab led to significant reductions in EASI scores compared to the placebo at week 16. The most significant decreases were seen in the groups receiving the highest dose of rocatinlimab every two weeks, with a mean reduction in EASI score of 61.1%. These improvements were maintained in most patients after treatment was discontinued.

The drug was generally well tolerated, with the most common adverse events being pyrexia (fever), nasopharyngitis (a common cold), chills, headache, aphthous ulcers, and nausea. There were no deaths reported in the study.


The study suggests that rocatinlimab may be an effective and safe treatment for moderate-to-severe atopic dermatitis. However, further research is needed to confirm these findings and to determine the optimal dose and duration of treatment.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.